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Abstract: Cardiac ryanodine receptor (RyR2) mutations are implicated in the potentially fatal cat-
echolaminergic polymorphic ventricular tachycardia (CPVT) and in atrial fibrillation. CPVT has
been successfully treated with flecainide monotherapy, with occasional notable exceptions. Reported
actions of flecainide on cardiac sodium currents from mice carrying the pro-arrhythmic homozygotic
RyR2-P2328S mutation prompted our explorations of the effects of flecainide on their RyR2 channels.
Lipid bilayer electrophysiology techniques demonstrated a novel, paradoxical increase in RyR2
activity. Preceding flecainide exposure, channels were mildly activated by 1 mM luminal Ca2+ and
1 µM cytoplasmic Ca2+, with open probabilities (Po) of 0.03 ± 0.01 (wild type, WT) or 0.096 ± 0.024
(P2328S). Open probability (Po) increased within 0.5 to 3 min of exposure to 0.5 to 5.0 µM cytoplasmic
flecainide, then declined with higher concentrations of flecainide. There were no such increases in a
subset of high Po channels with Po ≥ 0.08, although Po then declined with ≥5 µM (WT) or ≥50 µM
flecainide (P2328S). On average, channels with Po < 0.08 were significantly activated by 0.5 to 10 µM
of flecainide (WT) or 0.5 to 50 µM of flecainide (P2328S). These results suggest that flecainide can
bind to separate activation and inhibition sites on RyR2, with activation dominating in lower activity
channels and inhibition dominating in more active channels.
Keywords: RyR2; RyR2-P2328S; flecainide; catecholaminergic polymorphic ventricular tachycardia;
atrial fibrillation; RyR2 activation; RyR2 inhibition
1. Introduction
Normal cardiac function depends upon regulatory surface membrane ion channel
and transporter activity and the resulting Ca2+ release and reuptake processes between
the cytosol and the intracellular sarcoplasmic reticular (SR) Ca2+ store in its participating
cardiac myocytes. Mutations in proteins underlying these processes can lead to arrhythmic
conditions and cardiac failure [1]. Of these, mutations in the cardiac sarcoplasmic reticu-
lum (SR) ryanodine receptor (RyR2) Ca2+ release channel can increase channel opening
during diastole, with a consequent excess SR Ca2+ release. Cardiac ryanodine receptor
(RyR2) mutations have been associated with catecholaminergic polymorphic ventricular
tachycardia (CPVT) [2], ventricular fibrillation (VF) [3] and/or atrial fibrillation (AF) [4].
Recent studies reported that RyR2 channels from RyR2-P2328S mouse hearts modelling a
clinical CPVT variant showed increased activity at diastolic Ca2+ concentrations compared
to wild-type (WT) RyR2 channels [5]. This increased activity parallels pro-arrhythmic
effects of the mutation in mouse models and humans and has similar features to other
arrhythmogenic RyR2 mutations [6–10].
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The increases in diastolic cytosolic Ca2+ concentrations associated with these mu-
tations may activate surface membrane sodium calcium exchanger (NCX) activity. Its
electrogenic effects from extruding 1 Ca2+ in exchange for 3 Na+ ions can generate delayed
after-depolarisation (DAD) phenomena that can trigger pro-arrhythmic ectopic action
potentials, if reaching threshold voltage. Elevated cytosolic Ca2+ concentrations have also
been implicated in reducing sodium channel (NaV) activity [11,12]. This would compro-
mise action potential generation and conduction, producing a pro-arrhythmic re-entrant
substrate. Mouse RyR2-P2328S hearts demonstrated reduced Nav1.5 currents (INa) and
slowed action potential conduction velocities [7,13–15]. These pro-arrhythmic properties
were reduced by the established, anti-arrhythmic drug flecainide [7].
Flecainide is an established class Ic anti-arrhythmic Nav1.5 blocking agent. Yet, it
paradoxically rescued the reductions in INa and action potential wavelength in RyR2-
P2328S hearts, findings unexpected for a Nav1.5 blocker. Therefore, these findings may
reflect actions on other components of the excitation-contraction coupling pathway, such
as its more recently reported inhibitory actions on RyR2. Such findings prompted one
possible hypothesis suggesting a primary role for RyR2 in the anti-arrhythmic actions of
flecainide [6,7,16–18]. It was therefore of interest to compare the effects of flecainide on
RyR2 channels from RyR2-P2328S mice and their WT counterparts.
2. Materials and Methods
2.1. Harvesting of Mouse Hearts
WT and homozygous RyR2-P2328S inbred 129/Sv mice, age matched across 3 to
7 months in order to obtain a range across which would represent a similar distribution in
the human population, were killed by cervical dislocation in licensed institutional premises
under the UK Animals (Scientific Procedures) Act 1986. The hearts were rapidly excised
and transferred to an ice cold Krebs-Henseleit buffer (in mM: NaCl 119, NaHCO3 25, KCl 4,
KH2PO4 1.2, MgCl2 1, CaCl2 1.8, glucose 10 and Na-pyruvate 2; pH 7.4, 95% O2/5% CO2)
to rinse and remove excess tissue and blood. The whole heart was then snap frozen in
liquid N2. Hearts were couriered to Australia on dry ice and then stored at −80 ◦C.
2.2. Isolation of the RyR2 SR Vesicle Preparation
All steps of the SR vesicle preparation were performed on ice and/or at 4 ◦C. Five
to 7 hearts were homogenised in a cardiac homogenising buffer (CHB, containing in mM:
sucrose 290, imidazole 10, and NaN3 3, pH 6.9). The homogenate was then centrifuged
at 12,000× g for 20 min, then the pellet discarded and the supernatant centrifuged at
43,000× g for 2 h. The pellet was resuspended in Buffer A (CHB plus 649 mM KCl) and
centrifuged at 46,000× g for 1.5 h. The resulting pellet was resuspended in 125 µL of
buffer A per gm of mouse heart plus a protease inhibitor mixture and stored in 8 µL
aliquots at −80 ◦C. All individual protease inhibitors were obtained from Sigma Aldrich
(Castle Hill NSW, Australia) and were added to the final suspension at the following final
concentrations: benzamidine hydrochloride hydrate (catalogue # B6506) 1.0 mM; Pepstatin
A (catalogue # P4265) 2.1 µM; Leupeptin (catalogue # L2884) 1 µM; AEBSF/Pefabloc SC
(catalogue # 76307) 0.5 mM; Calpain Inhibitor I (catalogue # A6185) 3 µM; Calpain Inhibitor
II (Catalogue # A6060) 3 µM.
2.3. Single Channel Lipid Bilayer Recordings
Lipid bilayers were formed as previously described [5] by spreading a lipid mixture
(phosphatidylethanolamine, phosphatidylserine and phosphatidylcholine in n-decane)
across a 100 µm aperture in a partition separating the cis chamber and trans chambers. SR
vesicles were added to the cis solution so that, following incorporation, the cytoplasmic
surface of SR and RyR2 faced that solution, which was therefore equivalent to the cyto-
plasmic solution. SR vesicles were incorporated using a cytoplasmic (cis) incorporation
solution containing, in mM: 230 caesium methanesulfonate (CsMS); 20 CsCl; 1 CaCl2 and 10
tetraethylsulfamide (TES) pH 7.4. The luminal (trans) incorporation solution contained, in
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mM: 30 CsMS; 20 CsCl; 10 TES; pH 7.4, with a physiological luminal Ca2+ concentration of
1 mM. Following channel incorporation, CsMS was added to the trans solution to equalise
the concentration of the charge carrier in both solutions. Continuous current recording
began at this stage and continued for the duration of the experiment. The cis solution was
then exchanged with a recording solution, identical to the cis incorporation solution, except
that the cytoplasmic Ca2+ concentration was 1 µM. The solution was exchanged using a
back-to-back 10 mL syringe aspiration-perfusion system designed to effectively replace
the entire cis bathing solution. The Ca2+ concentration of the perfusion solution was set by
adding appropriate concentrations of BAPTA (determined using a Ca2+ electrode). The
cis solution was supplemented with flecainide to final concentrations of 0.5, 1, 5, 10, 50
and 100 µM. Experiments were performed at a room temperature of 19 ± 1 ◦C. Note that
the trans (luminal) Ca2+ concentration was maintained at its physiological level of 1 mM
throughout. Note also that the initial cytoplasmic Ca2+ concentration of 1 mM used for
vesicle incorporation was higher than the cellular range of 100 nM to 10 µM, but this was
required to facilitate channel incorporation.
2.4. Single Channel Lipid Bilayer Electrophysiology and Analysis
Electrodes in the solutions on either side of the bilayer were used to voltage clamp the
bilayer potential to −40 or +40 mV (Vcis—Vtrans) and to detect current flow through the
channel. The bilayer potential was switched between −40 mV and +40 mV every 30 s. The
open probability (Po), mean open time (To), and mean closed time (Tc) were measured over
60 to 90 s of recording in which only one channel opened in the bilayer, using the programs
Channel 2 (developed by PW Gage and M Smith, JCSMR) or Channel 3 (developed by NW
Laver, University of Newcastle). Threshold levels for channel opening were set to exclude
baseline noise at ∼20% of the maximum single channel conductance.
2.5. Statistics
The significance of differences between various parameters for all channel data were
assessed with Students t-test. Values are expressed as means ± standard errors of the mean
(SEM). Differences were considered significant with p < 0.05.
3. Results
Flecainide was applied to RyR2 channels incorporated into lipid bilayers over a range
of increasing drug concentrations from 0.5 to 100 µM (Methods). Channels were exposed
to each flecainide concentration for 2 to 3 min and 60 s to 90 s of channel activity analysed
at each potential. Neither ATP nor Mg2+ were included in the bathing solutions.
3.1. Overall Actions of Flecainide on WT and P2328S Channels
The control activity of channels is shown in Figure 1A. As previously reported, mutant
channels were more active than WT, with both more active at −40 mV than +40 mV [5].
Unexpectedly, the activity of both the WT and P2328S channels increased relative to control
with 5 µM flecainide, then returned towards control with 50 µM flecainide. There was
no voltage dependence in this action of flecainide in the channel records (Figure 1A) or
in channel gating parameters (Figure 1B). Therefore, values from both potentials are in-
cluded in all subsequent average data. Average control Po for WT channels of 0.03 ± 0.01
was significantly less than 0.096 ± 0.024 for P2328S channels, with the P2328S channels
having significantly shorter, closed durations and greater event frequency (130 ± 22.9 ms
and 26.02 ± 4.97 s−1, respectively) compared to the WT channels (324 ± 64.0 ms and
11.00 ± 4.28 s−1, respectively). Furthermore, the average Po in the P2328S channels re-
mained significantly higher than the WT with flecainide concentrations of 1.0 to 50 µM and
was maintained through shorter closures and higher opening frequencies.
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Figure 1. Actions of flecainide on individual wild type (WT) and P2328S RyR2 channels. (A) Channel currents before
addition of flecainide (upper) and with 5 µM flecainide (middle) and 50 µM flecainide (lower) at −40 mV (A) (I,II) and
+40 mV (A) (III,IV). Arrows indicate maximum open current. (B) Individual data for WT (n = 13) and P2328S (n = 17)
channels. Relative open probability (Po) (B) (I,II), mean open time (To) (B) (III,IV), mean closed time (Tc) (B) (V,VI) and open
frequency (Fo) (B) (VII,VIII) at +40 mV (circles) and −40 mV (triangles). Data for each channel is represented by symbols of
the same colour. The bar graphs show the mean values for each of the parameters at each flecainide concentration.
Curiously, the increase in Po shown by the individual channels, illustrated in Figure 1A,
is not reflected in the mean parameter values in Figure 1B, although activity of many chan-
nels, particularly WT with a low control Po increased with 0.5 and 1.0 µM flecainide. In
addition, the mean closed times tended to decrease and the event frequency to increase in
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the WT channels with 0.5 and 1.0 µM flecainide, changes that would be associated with
increased activity. The decline in activity with higher flecainide concentrations, especially
apparent in channels with high control Po values, was reflected in a tendency for Po to
decrease, associated with significantly longer closed times, consistent with flecainide inhibi-
tion of RyR2. On the other hand, the frequency of openings in the P2328S channels tended
to increase with 10 µM and 50 µM flecainide, a change not consistent with the decrease
in Po.
Apparent inconsistencies between the mean values in Figure 1B and individual chan-
nel data could arise because of the wide distribution of parameter values here (Figure 1B)
and reported in mouse, dog and human RyR2 [5,19,20]. With this wide range, the average
values became biased towards larger values. Accordingly, a more representative indication
of flecainide’s actions on individual channels was obtained by expressing values relative to
the internal control for each channel before exposure to the drug [21,22] (Figure 2A).
Figure 2. Actions of flecainide on relative parameter values for wild type (WT) and P2328S RyR2 channels. (A) Average
normalised data (mean ± SEM) for WT (n = 13) and P2328S (n = 17) channels. Relative open probability (Po) (A) (I,II), mean
open time (To) (A) (III,IV), mean closed time (Tc) (A) (V,VI) and open frequency (Fo) (A) (VII,VIII). Asterisks (*) indicate
significant (p < 0.05) changes from control. Blue # indicates significant (p < 0.05) differences between P2328S and WT.
(B) Individual maximum relative Po values with flecainide, plotted against control Po for WT (B) (I) and P2328S (B) (II).
Black circles, +40 mV; purple triangles, −40 mV. Maximum relative Po is the highest value recorded with flecainide. Values
below 1 indicate no increase in activity above control, but do not reflect the full decline in activity.
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3.2. Normalisation Reveals a Consistent Increase in Channel Activity with Flecainide
Consistent significant changes with flecainide emerged in the normalised data
(Figure 2A). The relative Po in the WT and P2328S channels increased significantly, reach-
ing a maximum between 1 to 5 µM and then decreasing as the drug concentrations were
further increased. The relative Po then declined to control levels with 50 µM of flecainide
in the WT and to significantly less than control levels in the P2328S channels with 100 µM
of flecainide. The increases in Po were associated with increases in event frequency.
An apparent influence of control activity on activation by flecainide was noted in
Figure 1 above. To explore this further, the maximum Po after exposure to flecainide was
plotted against the control Po for each channel (Figure 2B). Po increased above the SEM on
control activity (~1.3-fold) in 78% of WT channels with a low control Po but did not increase
in any channels with a Po greater than 0.08 (Figure 2B(I)). Thus Po = 0.08 formed a ceiling
above which there was no increase in WT activity. In contrast, there was no obvious ceiling
for increased activity in the P2328S channels (Figure 2B(II)). To explore gating changes
associated with increased or decreased activity, data was therefore sorted into high and
low activity groups using a threshold control Po of 0.08.
3.3. The Control Activity of Individual Channels Determines the Action of Flecainide
Examples of channels with a high control Po are shown in Figure 3A(I,II). The av-
erage relative Po in high activity WT channels did not change with the introduction of
0.5 and 1.0 µM of flecainide but fell significantly with flecainide concentrations of 5 to
50 µM (Figure 3B(I)). The average relative Po in the P2328S declined significantly with
concentrations of 50 and 100 µM of flecainide (Figure 2B(II)). Notably, the relative Po in
the WT channels with 50 µM of flecainide was significantly less than the Po of the P2328S
channels with 50 or 100 µM of flecainide. The decline in Po was associated with a signifi-
cant abbreviation of open times. WT channel closures became longer and open frequency
declined consistent with a reduced Po and reduced open duration. In contrast, the P2328S
channels exhibited a small but significant decrease in closed durations and increased open
frequency with higher flecainide concentrations, both opposing the reduced open time and
contributing to significantly smaller declines in Po. Average parameter values (Table 1)
generally reflect the changes in normalised values.
Table 1. Gating parameters for high or activity wild type (WT) and P2328S RyR2 channels before and during flecainide
exposure. Parameter values for WT and P2328S channels before adding flecainide ([Flec] = 0 µM) and with 0.5 µM to
50 µM (WT) or 100 µM (P2328S) flecainide. 100 µM flecainide not applied to WT channels (nd, not done). Mean ± SEM is
presented. Po, open probability; To, mean open time; Tc, mean closed time; Fo, frequency of opening. Asterisk (*) denotes
significant (p < 0.05) difference from control. Blue # denotes P2328S showing significant (p < 0.05) differences from WT.
[Flec] 0 µM 0.5 µM 1.0 µM 5 µM 10 µM 50 µM 100 µM
WILD TYPE
Po 0.147 ± 0.022 0.120 ± 0.024 0.142 ± 0.034 0.067 ± 0.032 * 0.039 ± 0.004 * 0.011 ± 0.005 * nd
To (ms) 4.18 ± 0.34 2.43 ± 0.05 3.14 ± 0.69 3.71 ± 2.28 1.37 ± 0.17 0.73 ± 0.22 * nd
Tc (ms) 26.65 ± 8.23 23.26 ± 8.62 25.17 ± 13.28 48.75 ± 11.93 35.39 ± 7.75 70.5 ± 11.6 * nd
Fo (s−1) 49.32 ± 19.67 62.34 ± 22.43 52.41 ± 17.40 22.57 ± 7.20 28.35 ± 5.70 14.40 ± 2.31 nd
P2328S
Po 0.241 ± 0.044 # 0.204 ± 0.065 0.227 ± 0.079 # 0.228 ± 0.083 0.201 ± 0.087 # 0.133 ± 0.040 *,# 0.116 ± 0.049
To (ms) 4.08 ± 0.72 4.01 ± 1.22 3.44 ± 1.09 3.98 ± 1.07 1.97 ± 0.40 * 1.23 ± 0.14 * 1.17 ± 0.13 *
Tc (ms) 15.07 ± 2.78 # 19.39 ± 4.70 24.55 ± 12.83 20.92 ± 7.86 # 11.43 ± 3.62 # 10.16 ± 2.83 # 10.50 ± 3.91
Fo (s−1) 60.58 ± 6.25 61.72 ± 14.74 66.00 ± 10.24 49.98 ± 6.78 # 92.89 ± 18.95 *,# 105.80 ± 26.53 *,# 95.76 ± 31.07 *
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Figure 3. Reduced activity of high control Po WT and P2328S channels. (A) Currents at −40 mV from channels with
control Po = 0.188 (wild type (WT), (A) (I) or 0.494 (P2328S, (A) (II)), before flecainide (upper) and with flecainide at 5 µM
(middle) and 50 µM (lower). Arrows indicate maximum open current. (B) Relative open probability (Po) (B) (I,II), mean
open time (To) (B) (III,IV), mean closed time (Tc) (B) (V,VI) and open frequency (Fo) (B) (VII,VIII). Data is mean ± SEM.
Asterisk (*), significant (p < 0.05) change from control. Blue #, significant (p < 0.05) difference between P2328S and WT,
@ significant (p < 0.05) differences between 0.5 or 1 µM and 100 µM flecainide. WT (n = 3) and P2328S (n = 6).
In marked contrast to the higher activity channels, an increase in Po dominated in
low activity channels (Figure 4A). Po peaked with 5 and 10 µM flecainide, then declined
as concentrations increased and became significantly less than the control values in the
P2328S, with concentrations reaching 100 µM flecainide. Event frequency changed with Po
particularly in the mutant channels, but there were no consistent changes in open or closed
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times in either channel type. Again, changes in the average parameter values generally
reflect the changes in normalised values (Table 2).
Figure 4. Increased activity of low control open probability (Po) wild type (WT) and P2328S channels. (A) Average relative
Po (A) (I,II), mean open time (To) (A) (III,IV), mean closed time (Tc) (A) (V,VI) and open frequency (Fo) (A) (VII,VIII) for
WT (n = 10) and P2328S (n = 11). (B) Average parameter values for WT (B) (I) and P2328S (B) (II). WT channels were not
exposed to 100 µM flecainide. In (B) data is mean ± SEM. (*), significant (p < 0.05) change from control. Blue #, significant
(p < 0.05) difference between WT and P2328S.
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The results in Figures 2 and 3 indicate that an increase in activity was associated with
an increase in opening frequency and reduced closed time, while the decline in activity
was associated with a reduced open time and event frequency.
Table 2. Gating parameters for high or activity wild type (WT) and P2328S RyR2 channels before and during flecainide
exposure. Parameter values for wild type (WT) and P2328S channels before adding flecainide ([Flec] = 0 µM) and with
0.5 µM to 50 µM (WT) or 100 µM (P2328S) flecainide. 100 µM flecainide not applied to WT channels (nd, not done). Mean
± SEM is presented. Po, open probability; To, mean open time; Tc, mean closed time; Fo, frequency of opening. Asterisk
(*) denotes significant (p < 0.05) difference from control. Blue # denotes P2328S showing significant (p < 0.05) differences
from WT.
[Flec] 0 µM 0.5 µM 1.0 µM 5 µM 10 µM 50 µM 100 µM
WILD TYPE
Po 0.009 ± 0.003 0.009 ± 0.002 0.015 ± 0.012 0.023 ± 0.012 0.011 ± 0.003 0.007 ± 0.002 nd
To (ms) 2.01 ± 0.31 1.63 ± 0.31 1.86 ± 0.18 4.43 ± 2.66 1.50 ± 0.34 1.67 ± 0.19 nd
Tc (ms) 387.4 ± 69.7 254.7 ± 57.6 249.1 ± 61.0 335.6 ± 71.4 355.3 ± 116.2 413.8 ± 154.7 nd
Fo (s−1) 4.03 ± 0.81 5.84 ± 1.24 8.82 ± 1.79 * 7.73 ± 2.52 6.54 ± 1.61 4.61 ± 1.34 nd
P2328S
Po 0.017 ± 0.005 # 0.028 ± 0.010 # 0.026 ± 0.013 0.025 ± 0.010 0.028 ± 0.018 0.019 ± 0.011 0.010 ± 0.011
To (ms) 2.08 ± 0.28 2.09 ± 0.41 2.03 ± 0.52 1.46 ± 0.05 1.15 ± 0.14 * 1.67 ± 0.29 1.64 ± 0.57
Tc (ms) 192.4 ± 27.16 # 113.8 ± 20.71 *,# 176.3 ± 43.20 152.6 ± 52.76 # 154.4 ± 69.40 207.8 ± 114.9 331.2 ± 267.5
Fo (s−1) 7.172 ± 0.935 # 12.79 ± 2.117 *,# 9.96 ± 1.570 16.26 ± 3.074 *,# 20.54 ± 7.924 *,# 10.92 ± 4.150 *,# 7.715 ± 6.665
4. Discussion
We report for the first time significant increases in the activity of isolated RyR2 chan-
nels from WT and P2328S mouse hearts following an application of low cytoplasmic
concentrations (0.5 to 10 µM) of flecainide. However, with further increased concentra-
tions, activity declined to significantly below control levels at 50 and 100 µM flecainide.
This result was consistent with flecainide binding to an activation site, dominating the
response at low flecainide concentrations, while binding to an inhibitory site with increased
concentrations, which reduced or even reversed this activation effect. The activation was
shifted to higher flecainide concentrations, reaching a peak between 5 and 10 µM in P2328S,
compared to 1 to 5 µM in WT channels. Since Po reflects the summation of both activation
and inhibition, these differences could be explained by either stronger activation or weaker
inhibition in P2328S compared to WT. It was surprising that the P2328S channels were
not more inhibited by flecainide than the WT, given that those channels were generally
more active than WT channels. However, this was consistent with activation dominating
the action of flecainide on mutant channels, possibly caused by changes in the activating
binding site as a result of the P2328S mutation. It should be reiterated that the aim of the
present study was to decipher the basic action of flecainide on RyR2 channel gating. It
would not be surprising if the flecainide’s action differed between isolated RyR2 channels
and RyR2 channels in myocytes, where the channels are subject to a multitude of other
modulatory influences. This is illustrated by the apparent dominance of activation in the
P2328S channels in contrast to flecainide inhibition of RyR2-mediated Ca2+ release in the
P2328S mouse [7].
These observations on isolated channels were obtained under conditions in which
currents through the individual channels were recorded for up to 90 min, with channel
parameters generally measured over 60 to 90 s at each flecainide concentration. The two to
ten-fold changes in channel activity with flecainide were maintained for many minutes.
RyR2 activity does not spontaneously change during bilayer experiments in the absence of
specific interventions, although Po can fluctuate by 10 to 20% over several minutes [23–25].
That RyR2 activity does not spontaneously increase or decrease during experimentation
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is evidenced by changes in Po with specific interventions being fully reversed when the
intervention is removed [26,27].
RyR2 activation by flecainide is a novel and unexpected, hitherto unreported, finding.
It should be noted however that the present experimental conditions differed from those of
previous studies. First, a number of earlier studies were made under conditions producing
high Po values (0.89–0.99) close to the 1.00 ceiling in the presence of 1 to 2 mM of cytoplasmic
ATP [16,21,28]. These almost maximal Po values could mask flecainide-mediated activation
as Po is unable to increase further even if there are further activating conformational changes
in the protein. However, a simple ceiling effect might not be the reason, because we did not
see activation in our high activity RyR2 channels where an average Po between 0.12 and 0.25
would have permitted a >two-fold increase in Po in the presence of a flecainide mediated
activation mechanism. In addition, some previous experiments were performed in the
presence of Mg2+ to lower Po to more physiological levels while in the presence of ATP [21].
Inclusion of either or both ATP and Mg2+ could potentially also reduce the activating effect
of flecainide. In this context, Bannister et al. [17], using only 2,3-butanedione monoxime
(BDM-) 4100 (C14H13N3OS)) to increase Po to 0.98 before flecainide addition, show weak
trends towards decreased closed times with flecainide, consistent with changes also seen
in the high activity of the P2328S channels, possibly due to the presence of an activating
influence. An additional factor that could contribute to activation being overlooked may
be flecainide concentration. We show the strongest effects of activation with 0.5 to 1.0 µM
flecainide, concentrations not generally explored in most previous studies which mainly
examine the effects of flecainide with concentrations ≥5 µM, and showed reduced activities
at ≥10 µM [16,21,28], similar to trends seen in the present observations.
In contrast to those previous studies [16,17,21], and as a result of the minimal ex-
perimental conditions in the present experiments, the RyR2 channels were studied in an
absence of other cytosolic regulatory binding factors such as ATP and Mg2+ [16,21]. This
minimised the number of potential interactions that might modify the structure of the
RyR2 and mask the effects of flecainide alone on channel activity, in other words that might
reveal the direct effects of flecainide on RyR2 gating. However, as with previous studies,
the channels in the present experiments maintained the vesicular RyR2 associations with
binding proteins, such as triadin, junctin, calsequestrin 2, junctaphilin and FKBP12 [5,29,30].
Importantly, the control Po values in the present study (0.001 to 0.4) covered much of the
physiological range. Systolic Po is ~0.4 [31], as in the high activity channels. Diastolic Po is
predicted to be 0.00001 to 0.00004 [32], too low for accurate single channel measurements.
Our low activity control Po (0.001 to 0.08) would however exist in late diastole particularly
in CPVT and in early systole.
Together the present and previous findings suggest possible dual activating and
inactivating effects of flecainide on RyR2. At the cellular level, this could be reflected
in differing reports of its in vivo actions in both suppressing Ca2+ waves in intact and
permeabilized myocytes, while increasing Ca2+ spark frequency [28]. In contrast, in intact
hearts from a homozygotic CPVT mouse model exhibiting compromised Nav1.5 function,
flecainide, despite being a Nav1.5 blocker, mediated anti-arrhythmic effects likely via the
inhibition of RyR2-mediated Ca2+ release [6,7,16,33]. This indirect, RyR2-mediated effect
may be the basis for the recent use of flecainide monotherapy in human CPVT, although
here individuals are usually heterozygotic and thus flecainide could be acting on both
WT and mutant RyR2 [34–36]. Flecainide’s direct pro-arrhythmic actions may continue
to reinforce the contra-indication of its use with structural heart disease [16,37], which
has been attributed to its direct Nav1.5 inhibitory effect and would be exacerbated by the
RyR2 activation reported here. The findings together are consistent with RyR2 being a
large molecule influenced by multiple activation and inhibition sites potentially targeted
by flecainide and variously located in RyR2’s peripheral and central cytoplasmic and
luminal domains all converging on gating mechanisms near the channel pore. The voltage
independence of the flecainide-mediated activation reported here would suggest a binding
site remote from the membrane in contrast to voltage-dependent inhibition, which suggests
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a site influenced by the membrane field [21]. Residue P2328 is situated on the HD1 Helical
Domain, which has long range interactions with gating regions near the RyR2 channel
pore [38–40], therefore compatible with a mutation that modifies the activating response to
flecainide.
5. Conclusions
There is an activation site for flecainide on the RyR2 channel that may not be accessible
under most cellular conditions but may become exposed under particular experimen-
tal or clinical situations. Flecainide activation at this site may contribute to reports of
occasional paradoxical proarrhythmic actions of flecainide. Nevertheless, the inhibitory
action likely dominates in high open probability RyR2 channels, contributing to its clin-
ical anti-arrhythmic efficacy in CPVT. Overall, the results underscore the importance of
understanding the underlying cause of an arrhythmia to ensure an appropriate therapeutic
strategy.
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